#### \_Meeting Roster\_

# ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

# Kenneth D. Burman, M.D. (Acting Chair) Chief, Endocrine Section Washington Hospital Center Washington, District of Columbia

#### Thomas P. Bersot, M.D., Ph.D.

Associate Investigator Gladstone Institute of Cardiovascular Disease San Francisco, California

# Michael A. Proschan, Ph.D.

Biostatistician Biostatistics Research Branch National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, Maryland

## Allison B. Goldfine, M.D.

Assistant Director of Clinical Research Joslin Diabetes Center, Research Division Boston, Massachusetts

# Katherine M. Flegal, Ph.D. Senior Research Scientist Distinguished Consultant National Center for Health Statistics Centers for Disease Control and Prevention Hyattsville, Maryland

#### Jessica W. Henderson, Ph.D.

Associate Professor Division of Health and Physical Education Western Oregon University Monmouth, Oregon

# Clifford J. Rosen, M.D.

Senior Staff Scientist Maine Center for Osteoporosis St. Joseph Hospital Bangor, Maine

## Eric Felner, M.D.

Emory University School of Medicine Department of Pediatrics Division of Endocrinology Atlanta, Georgia

# ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS, INDUSTRY REPRESENTATIVE (Non-Voting)

## Enrico P. Veltri, MD Group Vice President

Global Clinical Development Cardiovascular and Metabolic Diseases Shering-Plough Research Institute Kenilworth, New Jersey

# DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBER (Voting)

**Timothy S. Lesar, Pharm.D.** Director of Pharmacy Albany Medical Center Albany, New York

## **CENTER FOR DRUG EVALUATION AND RESEARCH Special Government Employees** (SGEs), TEMPORARY VOTING MEMBERS(Voting)

**Thomas Fleming, Ph.D** (Discussant + Speaker) Professor of Biostatistics University of Washington Seattle, Washington

#### Eric S. Holmboe, M.D., F.A.C.P.

Vice President for Evaluation Research Director, Clinical Performance Services American Board of Internal Medicine Philadelphia, Pennsylvania

#### Ruth S. Day, Ph.D.

Director, Medical Cognition Laboratory Duke University Durham, North Carolina

# **REGULAR GOVERNMENT EMPLOYEES (RGEs)** (Voting)

## Judith Fradkin, M.D.

Director Division of Diabetes, Endocrinology and Metabolic Diseases NIDDK, National Institutes of Health Bethesda, Maryland

## Peter Savage, M.D.

Division of Diabetes, Endocrinology and Metabolic Diseases NIDDK, National Institutes of Health Bethesda, Maryland

**Rebecca W. Killion** Patient Representative Bowie, Maryland

Marvin A. Konstam, M.D. Tufts-New England Medical Center Boston, Massachusetts

## CENTER FOR DRUG EVALUATION AND RESEARCH SGE, TEMPORARY NON-VOTING MEMBER (Non-Voting)

**Saul Genuth, M.D.** Case Western Reserve University Cleveland, Ohio

# CENTER FOR DRUG EVAULATION AND RESEARCH SGES GUEST SPEAKERS (Non-Voting)

Steve Nissen, M.D. (Limited to Speaking Only) Medical Director, Cleveland Clinic Cardiovascular Coordinating Center Department of Cardiovascular Medicine Cleveland, Ohio

## **Robert Califf, M.D.** (Limited to Speaking Only) Vice Chancellor for Clinical Research Duke University Durham, North Carolina

# CENTER FOR DRUG EVALUATION AND RESEARCH GUEST SPEAKERS (Non-Voting)

## David Nathan, M.D.

Director of the General Clinical Research Center and of the Diabetes Center at Massachusetts General Hospital, and a Professor of Medicine at Harvard Medical School.

## **Professor Rury Holman**

Professor of Diabetic Medicine Diabetes Trials Unit Director OCDEM, University of Oxford

# Robert E. Ratner, M.D.

Vice-President of Scientific Affairs MedStar Research Institute Hyattsville, Maryland

## Hertzel C. Gerstein MD MSc FRCPC

McMaster University Dept. of Medicine, Hamilton, Ontario, Canada

## FDA PARTICIPANTS (Non-Voting)

**Gerald Dal Pan, M.D., M.H.S.** Director Office of Surveillance and Epidemiology CDER, FDA

**John Jenkins, M.D.** Director Office of New Drugs CDER, FDA

Mary H. Parks, M.D. Director Division of Metabolism and Endocrinology Products CDER, FDA **Robert Temple, M.D.** Director Office of Medical Policy CDER, FDA

**Curtis Rosebraugh, M.D., M.P.H**. Acting Director Office of Drug Evaluation II CDER, FDA

**Hylton Joffe, M.D.** Lead Medical Officer Division of Metabolism and Endocrinology Products CDER, FDA